NCT05363449View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 17, 2022

Primary Completion Date

November 14, 2023

Study Completion Date

November 14, 2023

Conditions
Tinea CrurisTinea Pedis
Interventions
DRUG

UHE-103 Cream

UHE-103 is an investigational combinational therapy containing keratolytic and antifungal

DRUG

Naftin (naftifine hydrochloride) Cream

Naftin (naftifine hydrochloride) Cream, 2%. Topical cream containing active drug

Trial Locations (5)

77055

Site #4, Houston

77845

Site #3, College Station

78759

Site #2, Austin

91320

Site #5, Thousand Oaks

92123

Site #1, San Diego

All Listed Sponsors
lead

Therapeutics, Inc.

INDUSTRY